IL13 and pulmonary fibrosis: Tralokinumab, a human IL-13 neutralizing monoclonal IgG4 antibody, has been tested in patients with uncontrolled asthma [24], ulcerative colitis, [25] and rapidly progressive idiopathic pulmonary fibrosis [26].